FGF basic

FGF basic Molekülinformation

Englischer Name	Fibroblast growth factor 2	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	4	Target-Alias	FGF-2，Heparin-binding growth factor 2，Basic fibroblast growth factor，FGFB，bFGF，HBGF-2，FGF2，Fibroblast Growth Factor 2 (Basic)，Basic Fibroblast Growth Factor BFGF，Prostatropin，Fibroblast Growth Factor 2
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Fibroblast growth factor 2
Target-Alias	FGF-2，Heparin-binding growth factor 2，Basic fibroblast growth factor，FGFB，bFGF，HBGF-2，FGF2，Fibroblast Growth Factor 2 (Basic)，Basic Fibroblast Growth Factor BFGF，Prostatropin，Fibroblast Growth Factor 2
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	4
Höchste Forschungs- und Entwicklungsphase	Approved

FGF basic Produktliste

Attribut
Protein (7)Kits (1)
Produktbibliothek
Online (8)
Spezies
Human (8)
Etikett
Tag Free (6)His Tag & Avi Tag (1)- (1)
Marker
Unconjugated (6)Biotin-labeled (1)- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT BFF-H4117	Human	E. coli	Human FGF basic Protein, premium grade	In den Warenkorb legen
HOT BFF-H5115	Human	E. coli	Human FGF basic (154aa) Protein, premium grade	In den Warenkorb legen
HOT GMP-FGCH17	Human	E. coli	GMP Human FGF basic Protein	In den Warenkorb legen
BFF-H4118	Human	E. coli	Human FGF basic Protein, Research Grade	In den Warenkorb legen
BFF-H5113	Human	E. coli	Human FGF basic Superior Stable Mutant Protein, premium grade	In den Warenkorb legen
BFF-H5114	Human	E. coli	Human FGF basic Superior Stable Mutant Protein, Research Grade	In den Warenkorb legen
CEA-C082	Human	-	Human bFGF/FGF2 ELISA Kit	In den Warenkorb legen
FGC-H81E3	Human	E. coli	Biotinylated Human FGF basic Protein, Avitag™,His Tag (HPLC verified)	In den Warenkorb legen

Gesamtmenge8

FGF basic Molekülhintergrund

FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. bFGF is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. It is necessary in mouse-feeder cell dependent culture systems, as well as in feeder and serum-free culture systems.

FGF basic Molekülalias

FGF2,BFGF,FGFB,FGF basic,HBGF-2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Muparfostat sodium	PI-88	Phase 3 Clinical	Australian National University	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Prostatic Neoplasms; Skin Melanoma; Solid tumours	Details
RBM-007	ID3 (21); APT-F2; RBM-007	Phase 2 Clinical	Ribomic	Achondroplasia; Macular Degeneration	Details
Fibroblast growth factor 2 gene therapy (ID Pharma)	SeV-10101; SEV-10101; DVC-10101; BF-30	Phase 2 Clinical	Dnavec	Arterial Occlusive Diseases; Intermittent Claudication; Ischemia; Peripheral Arterial Disease; Peripheral arterial occlusive disorders	Details
Recombinant Human Epidermal Growth Factor Derivative Gel (Uni-Bio Science)		Phase 1 Clinical	Uni-Bio Science Group	Wounds and Injuries	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Thalidomide	NSC-66847; NSC-527179; K-17; FPF-300; FPF300	Approved	Celgene Corp	Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled	Mainland China	Leprosy, Lepromatous; Multiple Myeloma	Changzhou Pharmaceutical Factory	1982-01-01	Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms	Details